• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1266338 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type) @3 t8 b2 s9 _9 ^
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
$ t9 c1 i  }7 |7 F- |1 t! o/ E' ]+ Author Affiliations
$ y* Y- x% d5 s+ P6 `" U  Z% F+ w8 _3 ?1 F( r5 E7 k6 \; @1 B! u% a
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . a; J! A7 }# _  d( E
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) @- E; z$ E. F
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # p* i( q* p0 ~0 A  z5 b/ |! `6 T
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
9 y: g8 s0 t# Z  u+ M6 B6 y5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
9 w, ~1 U7 W5 V% c- T# f/ C7 `; H3 ]6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
  U5 c5 E& \5 A# N5 B# b7Kinki University School of Medicine, Osaka 589-8511, Japan
" |3 F3 p# ^* b5 m8Izumi Municipal Hospital, Osaka 594-0071, Japan : K" Z# }: S" v3 n5 o2 k$ i1 M
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 3 Q$ |5 w3 a* I9 P! G
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 3 n  Z, p$ l; L0 Z$ w& t7 O
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 9 l! s% h( @) P3 c! P
+ t( U, d, H0 _$ O' s
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
+ M6 n$ L& M. n9 Q# B: Q+ x: ]) E5 @0 {4 ?5 B% c, L4 d7 V
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
, e" t8 l$ }. K) t# t7 I0 H2 i6 }
& }; W' ?' Z$ f4 q. |; b8 B$ EAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
' j- t* k/ b/ \" W8 s9 U/ U) I. t$ W, ?/ y; L
Published online on: Thursday, December 1, 2011 - S5 ?& P4 j7 }6 x9 t3 s( p7 t
3 _4 t. P2 ], f' w! u" v: T: e
Doi: 10.3892/ol.2011.507 ' ]  S2 P  h  i" |# B! Q& K: `
$ P& w5 ]9 c* }  q: c8 _4 b1 ]
Pages: 405-410 ' A" n3 {2 ]$ @2 M1 G4 X/ w8 I% d$ _  g

5 b2 u- L7 Y0 q4 T' d6 e5 b3 |Abstract:$ v  ]7 K. T& e- W
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.: d: B, w/ x9 f0 k4 |) A* m9 C

5 x( q# z# d  S
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population6 {& v, ~& a- ]$ e1 c
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 . B6 z5 j6 H7 `$ O
+ Author Affiliations
  Y* h7 c% u% J: O. [7 }1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu * t, d8 k2 U) t+ b
2Department of Thoracic Surgery, Kyoto University, Kyoto # v3 {! ^5 [' E
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan ( }1 k2 O% G- z4 M* q6 k- h
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 0 a" [& X8 ]3 v+ c" N4 h) S: q
Received September 3, 2010. , T* W# ^& e& S" r, c6 N+ J% X1 W
Revision received November 11, 2010.
3 b4 g( z+ A) Y# NAccepted November 17, 2010.
' V. j5 y# Q% [! Z, QAbstract! t! v* o8 ]! X/ \% R& W
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
! k: t( w" i/ ~! s8 i- E  JPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
$ a: f8 m8 L' ^3 H9 lResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
) \" O- [; o% U. L* ]Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. % c  ~& B* L% N/ ]7 d. A( m) g3 Z3 q
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
" @# a: h+ U  D今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?- S3 ~- J1 R' v9 l( N
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
1 `, M# U% |: i4 M* O( t3 s4 Dhttp://clinicaltrials.gov/ct2/show/NCT01523587
/ O$ g8 v' c7 f3 i7 M+ j& k# O8 M$ Q/ D! H
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC( F7 q& t9 Y/ K* J3 b8 v2 C4 U
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
, [( M5 |+ a( c7 n" E0 k4 U& K% D3 X6 p5 G* m" b  q6 _
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。1 X# U. i0 z  W5 f7 X: r& j# O  O
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 * V# }+ {/ R5 E! l
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。# s, m+ K5 v$ T( @! O4 k% U) w
至今为止,未出 ...
% e% m! @' u1 i" ]8 ]( K' `9 U2 ]+ K
没有副作用是第一追求,效果显著是第二追求。
0 ^* m8 X, I& L9 K不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表